Company: Zuyder Pharmaceuticals
Using Zuyder’s novel technology the Master’s Team will create a semi-automated process for the investigation of novel protein interactions in three disease states determined by Zuyder: Bone growth disorders, vascularization of tumors, and Alzheimers will be explored using this technology. In addition, the competitive landscape of Zuyder will be explored. Companies using similar technology and investigating similar disease states will be analyzed. A business plan for the development and/or licensing of any lead targets will also be generated. Academic personnel with expertise in each of the disease states will be identified and contacted with regard to future collaborations.